These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 30674687)
1. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687 [TBL] [Abstract][Full Text] [Related]
2. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. Préaud E; Largeron N J Med Econ; 2013; 16(6):763-76. PubMed ID: 23565814 [TBL] [Abstract][Full Text] [Related]
3. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review. Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098 [TBL] [Abstract][Full Text] [Related]
4. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718 [TBL] [Abstract][Full Text] [Related]
5. The economic burden of human papillomavirus-related precancers and cancers in Sweden. Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241 [TBL] [Abstract][Full Text] [Related]
7. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group. Marcellusi A; Capone A; Favato G; Mennini FS; Baio G; Haeussler K; Bononi M; Clin Ther; 2015 Jan; 37(1):156-167.e4. PubMed ID: 25487083 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study. Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625 [TBL] [Abstract][Full Text] [Related]
10. The economic burden of noncervical human papillomavirus disease in the United States. Hu D; Goldie S Am J Obstet Gynecol; 2008 May; 198(5):500.e1-7. PubMed ID: 18455524 [TBL] [Abstract][Full Text] [Related]
11. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. Olsen J; Jørgensen TR; Kofoed K; Larsen HK BMC Public Health; 2012 Dec; 12():1082. PubMed ID: 23244352 [TBL] [Abstract][Full Text] [Related]
12. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Woodhall SC; Jit M; Cai C; Ramsey T; Zia S; Crouch S; Birks Y; Newton R; Edmunds WJ; Lacey CJ Sex Transm Dis; 2009 Aug; 36(8):515-21. PubMed ID: 19543143 [TBL] [Abstract][Full Text] [Related]
13. Health and economic implications of HPV vaccination in the United States. Kim JJ; Goldie SJ N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299 [TBL] [Abstract][Full Text] [Related]
14. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES]. Malinova M Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767 [TBL] [Abstract][Full Text] [Related]
15. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art. Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829 [TBL] [Abstract][Full Text] [Related]
16. Quality of life valuations of HPV-associated cancer health states by the general population. Conway EL; Farmer KC; Lynch WJ; Rees GL; Wain G; Adams J Sex Transm Infect; 2012 Nov; 88(7):517-21. PubMed ID: 22645393 [TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228 [TBL] [Abstract][Full Text] [Related]
18. Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea. Choi I; Lee D; Son KB; Bae S BMC Public Health; 2020 Jun; 20(1):1035. PubMed ID: 32600300 [TBL] [Abstract][Full Text] [Related]
19. The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances. Goodman E; Reuschenbach M; Viering T; Luzak A; Greiner W; Hampl M; Jacob C Arch Gynecol Obstet; 2024 Nov; 310(5):2639-2646. PubMed ID: 39230793 [TBL] [Abstract][Full Text] [Related]
20. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]